€3bn heartburn for AstraZeneca

Drug firm AstraZeneca saw almost €3bn wiped off its value today after it lost a key patent on best-selling heartburn treatment Nexium.

AstraZeneca said it was “disappointed” with the decision by the European Patent Office (EPO) to withdraw the patent for Nexium.